Risk Factors of Levofloxacin–Resistant Escherichia coli Isolation

Abstract

  Fluoroquinolone drugs are commonly used to treat respiratory tract and urinary tract infections. However, in recent years, resistance to fluoroquinolone drugs has been emerging among Escherichia coli strains. LVFX is a standard fluoroquinolone drug, so monitoring is necessary to identify resistance with increased use. The data from adult (≧18 years old) inpatients who were administered LVFX for infections caused by E. coli between July 2009 and March 2012 was analyzed. LVFX-resistant E. coli was associated with the history of hospitalization, underlying diseases such as malignant tumor and respiratory disorder, indwelling of urinary catheter, and the use of fluoroquinolone drugs within the previous 6 months. We should reconsider the use of LVFX in patients with such factors.